HRP20200101T1 - Glikopeptidni pripravci - Google Patents
Glikopeptidni pripravci Download PDFInfo
- Publication number
- HRP20200101T1 HRP20200101T1 HRP20200101TT HRP20200101T HRP20200101T1 HR P20200101 T1 HRP20200101 T1 HR P20200101T1 HR P20200101T T HRP20200101T T HR P20200101TT HR P20200101 T HRP20200101 T HR P20200101T HR P20200101 T1 HRP20200101 T1 HR P20200101T1
- Authority
- HR
- Croatia
- Prior art keywords
- alanine
- preparation
- glycopeptide antibiotic
- amino acid
- acetyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 title 1
- 102000002068 Glycopeptides Human genes 0.000 title 1
- 108010015899 Glycopeptides Proteins 0.000 title 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 21
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 20
- 235000001014 amino acid Nutrition 0.000 claims 16
- 150000001413 amino acids Chemical class 0.000 claims 16
- 238000002360 preparation method Methods 0.000 claims 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 12
- KTHDTJVBEPMMGL-GSVOUGTGSA-N n-acetylalanine Chemical compound OC(=O)[C@@H](C)NC(C)=O KTHDTJVBEPMMGL-GSVOUGTGSA-N 0.000 claims 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 9
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 8
- 229960003104 ornithine Drugs 0.000 claims 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 7
- 239000004475 Arginine Substances 0.000 claims 7
- 239000004471 Glycine Substances 0.000 claims 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 7
- 239000004472 Lysine Substances 0.000 claims 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 7
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 7
- 235000009697 arginine Nutrition 0.000 claims 7
- 235000005772 leucine Nutrition 0.000 claims 7
- 235000018977 lysine Nutrition 0.000 claims 7
- 235000004400 serine Nutrition 0.000 claims 7
- 239000004474 valine Substances 0.000 claims 7
- 235000014393 valine Nutrition 0.000 claims 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 6
- OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 claims 6
- 235000004279 alanine Nutrition 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000003186 pharmaceutical solution Substances 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- KGPGQDLTDHGEGT-JCIKCJKQSA-N zeven Chemical compound C=1C([C@@H]2C(=O)N[C@H](C(N[C@H](C3=CC(O)=C4)C(=O)NCCCN(C)C)=O)[C@H](O)C5=CC=C(C(=C5)Cl)OC=5C=C6C=C(C=5O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@H](O5)C(O)=O)NC(=O)CCCCCCCCC(C)C)OC5=CC=C(C=C5)C[C@@H]5C(=O)N[C@H](C(N[C@H]6C(=O)N2)=O)C=2C(Cl)=C(O)C=C(C=2)OC=2C(O)=CC=C(C=2)[C@H](C(N5)=O)NC)=CC=C(O)C=1C3=C4O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O KGPGQDLTDHGEGT-JCIKCJKQSA-N 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 108010053950 Teicoplanin Proteins 0.000 claims 2
- 108010059993 Vancomycin Proteins 0.000 claims 2
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 claims 2
- 229960002488 dalbavancin Drugs 0.000 claims 2
- 108700009376 dalbavancin Proteins 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 229960001607 oritavancin Drugs 0.000 claims 2
- 108010006945 oritavancin Proteins 0.000 claims 2
- VHFGEBVPHAGQPI-MYYQHNLBSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-MYYQHNLBSA-N 0.000 claims 2
- 229960001608 teicoplanin Drugs 0.000 claims 2
- 229960005240 telavancin Drugs 0.000 claims 2
- 108010089019 telavancin Proteins 0.000 claims 2
- ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 claims 2
- 229960003165 vancomycin Drugs 0.000 claims 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 2
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 1
- 229930195711 D-Serine Natural products 0.000 claims 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims 1
- 229930182819 D-leucine Natural products 0.000 claims 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims 1
- 229930182831 D-valine Natural products 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- 229930064664 L-arginine Natural products 0.000 claims 1
- 235000014852 L-arginine Nutrition 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Claims (30)
1. Pripravak koji sadrži glikopeptidni antibiotik i pomoćnu tvar odabranu od N-acetil-D-Alanina ili N-acetil-Glicina za uporabu kao lijek, pri čemu je pripravak tekući pripravak.
2. Pripravak za uporabu prema zahtjevu 1, pri čemu je pripravak vodeni pripravak.
3. Pripravak za uporabu prema zahtjevu 2 koji ima pH od oko 3-6 i dalje sadrži aminokiselinu.
4. Pripravak za uporabu prema zahtjevu 3, pri čemu je koncentracija glikopeptidnog antibiotika oko 0.1-20 % w/V.
5. Pripravak za uporabu prema zahtjevu 4, pri čemu je koncentracija glikopeptidnog antibiotika oko 0.1-1 % w/V; i aminokiselina je odabrana od Glicina, Alanina, Serina, Leucina, Valina, Lizina, Arginina ili Ornitina; i pomoćna tvar je N-acetil-D-Alanin.
6. Pripravak za uporabu prema zahtjevu 4, pri čemu je koncentracija glikopeptidnog antibiotika oko 0.1-1 % w/V; i aminokiselina je odabrana od Glicina, Alanina, Serina, Leucina, Valina, Lizina, Arginina ili Ornitina; i pomoćna tvar je N-acetil-D-Alanin; pri čemu su glikopeptidni antibiotik, aminokiselina i N-acetil-D-Alanin prisutni u molarnom omjeru od oko 1:5:5 do 1:40:40.
7. Pripravak za uporabu prema zahtjevu 1, pri čemu je glikopeptidni antibiotik Vankomicin, Teikoplanin, Telavancin, Dalbavancin ili Oritavancin.
8. Pripravak za uporabu prema zahtjevu 4, pri čemu je koncentracija glikopeptidnog antibiotika oko 1-10 % w/V; i aminokiselina je odabrana od Glicina, Alanina, Serina, Leucina, Valina, Lizina, Arginina ili Ornitina; i pomoćna tvar je N-acetil-D-Alanin.
9. Pripravak za uporabu prema zahtjevu 4, pri čemu je koncentracija glikopeptidnog antibiotika oko 1-10 % w/V; i aminokiselina je odabrana od Glicina, Alanina, Serina, Leucina, Valina, Lizina, Arginina ili Ornitina; i pomoćna tvar je N-acetil-D-Alanin; te pri čemu su glikopeptidni antibiotik, aminokiselina i N-acetil-D-Alanin prisutni u molarnom omjeru od oko 1:1:1 do 1:10:10.
10. Farmaceutski pripravak koji sadrži glikopeptidni antibiotik; i pomoćnu tvar odabranu od N- acetil-D-Alanina ili N-acetil-Glicina, pri čemu je pripravak u tekućem obliku.
11. Farmaceutski pripravak prema zahtjevu 10, pri čemu je farmaceutski pripravak pripremljen za parenteralnu primjenu,
12. Farmaceutski pripravak prema zahtjevima 10 ili 11, pri čemu je pripravak vodeni pripravak.
13. Farmaceutski pripravak prema bilo kojem od zahtjeva 10 do 12, koji dalje sadrži aminokiselinu.
14. Farmaceutski pripravak prema zahtjevu 13, pri čemu je aminokiselina odabrana od Glicina, Alanina, Serina, Leucina, Valina, Lizina, Arginina ili Ornitina.
15. Farmaceutski pripravak prema zahtjevu 13, pri čemu je aminokiselina odabrana od D- Alanina, D-Serina, D-Leucina, D-Valina, L-Lizina, D-Lizina, L-Ornitina, D-Ornitina ili L- Arginina.
16. Farmaceutski pripravak prema bilo kojem od zahtjeva 12-15 koji imapH od oko 3-6.
17. Farmaceutski pripravak prema zahtjevu 13, pri čemu je molarni omjer aminokiseline prema glikopeptidnom antibiotiku od oko 0.5:1 do 40:1.
18. Farmaceutski pripravak prema zahtjevu 10, pri čemu je glikopeptidni antibiotik Vankomicin, Teikoplanin, Telavancin, Dalbavancin ili Oritavancin.
19. Farmaceutski pripravak prema bilo kojem od zahtjeva 13-16, koji dalje sadrži organsko otapalo odabrano od etanola ili polietilen glikola, pri čemu je koncentracija organskog otapala 50 % V/V ili manje.
20. Farmaceutski pripravak prema zahtjevu 12, pri čemu je farmaceutska otopina stabilna barem 4 tjedna na 25 stupnjeva Celzijevih, kako je prikazano određivanjem količine glikopeptidnog antibiotika koji preostaje u farmaceutskoj otopini nakon barem 4 tjedna na 25 stupnjeva Celzijevih, i pri čemu je količina glikopeptidnog antibiotika koja preostaje u farmaceutskoj otopini između 85 % i 100 %.
21. Farmaceutski pripravak prema zahtjevu 10, pri čemu je koncentracija glikopeptidnog antibiotika oko 0,1-20 % w/V.
22. Farmaceutski pripravak prema zahtjevu 10 koji sadrži 0,5-15 % w/V glikopeptidnog antibiotika i N-acetil-D-Alanin u molarnom omjeru od 1:1-1:40 i aminokiselinu.
23. Farmaceutski pripravak prema zahtjevu 12 koji sadrži oko 0,5-15 % w/V glikopeptidnog antibiotika i N-acctil-D-Alanin u molarnom omjeru od oko 1:1-1:40 koji ima pH od oko 3-6 i dalje sadrži aminokiselinu.
24. Farmaceutski pripravak prema zahtjevu 12 koji sadrži oko 0.5-15% w/V glikopeptidnog antibiotika i N-acetil-D-Alanin u molarnom omjeru od oko 1:1-1:40 koji ima pH od oko 3-6 i dalje sadrži aminokiselinu odabranu od Serina, Leucina, Valina, Lizina, Arginina i Ornitina.
25. Uporaba pomoćne tvari odabrane od N-acetil-D-Alanina ili N-acetil-Glicina za stabiliziranje farmaceutske otopine koja sadrži glikopeptidni antibiotik.
26. Postupak proizvodnje stabilne vodene farmaceutske otopine koji sadrži korake miješanja glikopeptidnog antibiotika i pomoćne tvari odabrane od N-acetil-D-Alanina ili N-aeetil-Glicina.
27. Postupak prema zahtjevu 26, pri čemu je koncentracija glikopeptidnog antibiotika oko 0.1-20 %w/V.
28. Postupak prema zahtjevu 26, koji dalje sadrži dodavanje aminokiseline.
29. Postupak prema zahtjevu 28, pri čemu je aminokiselina odabrana od Glicina, Alanina, Serina, Leucina, Valina, Lizina, Arginina ili Ornitina.
30. Postupak prema zahtjevu 29, koji dalje sadrži prilagođavanje pH otopine na između oko pH 3-6.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076400P | 2014-11-06 | 2014-11-06 | |
| US201562168749P | 2015-05-30 | 2015-05-30 | |
| EP15791287.4A EP3215173B8 (en) | 2014-11-06 | 2015-11-06 | Glycopeptide compositions |
| PCT/EP2015/075918 WO2016071495A1 (en) | 2014-11-06 | 2015-11-06 | Glycopeptide compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200101T1 true HRP20200101T1 (hr) | 2020-04-03 |
Family
ID=54478023
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200101TT HRP20200101T1 (hr) | 2014-11-06 | 2020-01-21 | Glikopeptidni pripravci |
| HRP20210342TT HRP20210342T8 (hr) | 2014-11-06 | 2021-03-01 | Pripravci glikopeptida |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210342TT HRP20210342T8 (hr) | 2014-11-06 | 2021-03-01 | Pripravci glikopeptida |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US10188697B2 (hr) |
| EP (4) | EP4147710A1 (hr) |
| JP (2) | JP6797795B2 (hr) |
| KR (2) | KR102603756B1 (hr) |
| CN (1) | CN107073072B (hr) |
| AU (1) | AU2015341763B2 (hr) |
| BR (1) | BR112017009405B1 (hr) |
| CA (1) | CA2964524A1 (hr) |
| CL (1) | CL2017001139A1 (hr) |
| CO (1) | CO2017005391A2 (hr) |
| CR (1) | CR20170234A (hr) |
| CY (2) | CY1122960T1 (hr) |
| DK (2) | DK3215173T3 (hr) |
| EA (1) | EA035368B1 (hr) |
| ES (2) | ES2852550T3 (hr) |
| HR (2) | HRP20200101T1 (hr) |
| HU (2) | HUE049857T2 (hr) |
| IL (1) | IL252120B (hr) |
| MX (1) | MX2017005749A (hr) |
| NZ (1) | NZ731955A (hr) |
| PH (1) | PH12017500720A1 (hr) |
| PL (2) | PL3542812T3 (hr) |
| PT (2) | PT3542812T (hr) |
| RS (2) | RS61418B1 (hr) |
| SA (1) | SA517381446B1 (hr) |
| SG (1) | SG11201703568WA (hr) |
| SI (2) | SI3542812T1 (hr) |
| TN (1) | TN2017000182A1 (hr) |
| WO (1) | WO2016071495A1 (hr) |
| ZA (1) | ZA201702767B (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201703568WA (en) * | 2014-11-06 | 2017-05-30 | Xellia Pharmaceuticals Aps | Glycopeptide compositions |
| WO2017111601A1 (en) * | 2015-12-24 | 2017-06-29 | Universiteit Leiden | Composition and method for treating infections caused by vancomycin-resistant infectious agents in a subject |
| WO2017194385A1 (en) * | 2016-05-09 | 2017-11-16 | Xellia Pharmaceuticals Aps | Stabilized glycopeptide antibiotic formulations |
| EP3544616A4 (en) * | 2016-11-23 | 2020-12-09 | Gufic Biosciences Limited | LYOPHILIZED PHARMACEUTICAL COMPOSITIONS OF DALBAVANCIN |
| JP7118412B2 (ja) * | 2017-07-31 | 2022-08-16 | 東洋製薬化成株式会社 | バンコマイシン懸濁液充填カプセル製剤 |
| CN109725101B (zh) * | 2017-10-31 | 2021-11-19 | 正大天晴药业集团股份有限公司 | 盐酸特拉万星原料中有关物质的检测方法 |
| CN109078001B (zh) * | 2018-09-21 | 2021-05-07 | 深圳浦瑞健康科技有限公司 | 一种万古霉素纳米脂质体组合物及其制备方法 |
| AU2020237983A1 (en) | 2019-03-08 | 2021-10-07 | Emphascience, Inc. | Stable pharmaceutical formulations of peptide and protein drugs |
| US11433115B2 (en) * | 2020-10-30 | 2022-09-06 | Somerset Therapeutics, Llc | Glycopeptide antibiotics liquid formulations and methods and uses thereof |
| EP4014965A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
| EP4014969A1 (en) * | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
| WO2022234036A1 (en) * | 2021-05-07 | 2022-11-10 | Xellia Pharmaceuticals Aps | Oral liquid vancomycin formulations |
| CN115804832A (zh) * | 2021-09-14 | 2023-03-17 | 海南普利制药股份有限公司 | 一种万古霉素水溶液组合物 |
| WO2023171588A1 (ja) * | 2022-03-08 | 2023-09-14 | 国立大学法人大阪大学 | 抗菌薬を含有するｐｌｇａ製剤 |
| GB202207344D0 (en) | 2022-05-19 | 2022-07-06 | Arecor Ltd | Novel composition |
| GB202207345D0 (en) | 2022-05-19 | 2022-07-06 | Arecor Ltd | Novel composition |
| WO2024079224A1 (en) * | 2022-10-12 | 2024-04-18 | Xellia Pharmaceuticals Aps | Liquid dalbavancin composition |
| WO2024079223A1 (en) * | 2022-10-12 | 2024-04-18 | Xellia Pharmaceuticals Aps | Liquid dalbavancin composition |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4670258A (en) | 1984-02-10 | 1987-06-02 | Vanderbilt University | Storable prepackaged aqueous solutions of vancomycin |
| TW457248B (en) | 1994-01-28 | 2001-10-01 | Lilly Co Eli | Glycopeptide antibiotic derivatives |
| AU1407197A (en) | 1995-12-01 | 1997-06-19 | Eli Lilly And Company | Stable vancomycin hydrochloride solutions |
| JPH1180021A (ja) | 1997-09-02 | 1999-03-23 | Kayaku:Kk | バンコマイシン注射剤 |
| US6800608B2 (en) | 2001-06-22 | 2004-10-05 | Beckman Coulter, Inc. | Homogeneous assay of vancomycin using a stable particle-vancomycin conjugate, a novel rate enhancer, and a novel dose response modulator |
| JP2005521712A (ja) * | 2002-03-26 | 2005-07-21 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | 弱塩基の可溶化 |
| GB0212622D0 (en) * | 2002-05-31 | 2002-07-10 | Natural Technologies Group Ltd | Bacterial transforming agent |
| JP2006506442A (ja) | 2002-07-09 | 2006-02-23 | ポイント セラピューティクス， インコーポレイテッド | ボロプロリン化合物併用療法 |
| CN1802090A (zh) * | 2002-07-09 | 2006-07-12 | 尖端医疗有限公司 | 硼脯氨酸化合物组合治疗 |
| AU2003294262B2 (en) | 2002-11-18 | 2007-08-23 | Vicuron Pharmaceuticals Inc. | Methods of administering dalbavancin for treatment of bacterial infections |
| CN101080221A (zh) | 2005-02-14 | 2007-11-28 | 维纳斯药业有限公司 | 抗药性细菌感染疾病的肠胃外综合治疗 |
| CN1857716A (zh) * | 2006-03-14 | 2006-11-08 | 浙江大学 | 注射用盐酸万古霉素及其制备方法 |
| JP2008201778A (ja) * | 2007-01-25 | 2008-09-04 | Mochida Pharmaceut Co Ltd | バンコマイシン液状製剤 |
| US20090186819A1 (en) * | 2007-12-11 | 2009-07-23 | Marieve Carrier | Formulation of insulinotropic peptide conjugates |
| JP2011080021A (ja) | 2009-10-09 | 2011-04-21 | Bridgestone Corp | 熱可塑性エラストマー組成物及びその成形体 |
| AU2012254999B2 (en) * | 2011-05-19 | 2016-02-11 | Savara, Inc. | Dry powder vancomycin compositions and associated methods |
| WO2014026052A1 (en) | 2012-08-08 | 2014-02-13 | Vanderbilt University | Composition with biofilm dispersal agents |
| ES2743039T3 (es) * | 2012-11-29 | 2020-02-18 | Insmed Inc | Formulaciones de vancomicina estabilizada |
| CN104043104B (zh) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | 含盐酸万古霉素的喷雾干粉及其工业化制备方法 |
| WO2014194296A1 (en) | 2013-05-30 | 2014-12-04 | Scidose, Llc | Formulations of vancomycin |
| US10959946B2 (en) | 2014-03-14 | 2021-03-30 | Azurity Pharmaceuticals, Inc. | Composition and method for vancomycin oral liquid |
| SG11201703568WA (en) * | 2014-11-06 | 2017-05-30 | Xellia Pharmaceuticals Aps | Glycopeptide compositions |
| WO2017194385A1 (en) | 2016-05-09 | 2017-11-16 | Xellia Pharmaceuticals Aps | Stabilized glycopeptide antibiotic formulations |
| US11433115B2 (en) | 2020-10-30 | 2022-09-06 | Somerset Therapeutics, Llc | Glycopeptide antibiotics liquid formulations and methods and uses thereof |
| EP4014965A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
| EP4014969A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
-
2015
- 2015-11-06 SG SG11201703568WA patent/SG11201703568WA/en unknown
- 2015-11-06 DK DK15791287.4T patent/DK3215173T3/da active
- 2015-11-06 HU HUE15791287A patent/HUE049857T2/hu unknown
- 2015-11-06 CR CR20170234A patent/CR20170234A/es unknown
- 2015-11-06 EP EP22203229.4A patent/EP4147710A1/en active Pending
- 2015-11-06 KR KR1020177015221A patent/KR102603756B1/ko active IP Right Grant
- 2015-11-06 EA EA201790997A patent/EA035368B1/ru unknown
- 2015-11-06 KR KR1020237020985A patent/KR20230096142A/ko not_active Application Discontinuation
- 2015-11-06 MX MX2017005749A patent/MX2017005749A/es unknown
- 2015-11-06 RS RS20210108A patent/RS61418B1/sr unknown
- 2015-11-06 AU AU2015341763A patent/AU2015341763B2/en active Active
- 2015-11-06 TN TN2017000182A patent/TN2017000182A1/en unknown
- 2015-11-06 EP EP15791287.4A patent/EP3215173B8/en not_active Revoked
- 2015-11-06 US US15/524,653 patent/US10188697B2/en active Active
- 2015-11-06 PT PT191748490T patent/PT3542812T/pt unknown
- 2015-11-06 EP EP19174849.0A patent/EP3542812B1/en active Active
- 2015-11-06 ES ES19174849T patent/ES2852550T3/es active Active
- 2015-11-06 RS RS20200080A patent/RS59851B1/sr unknown
- 2015-11-06 NZ NZ731955A patent/NZ731955A/en unknown
- 2015-11-06 DK DK19174849.0T patent/DK3542812T3/da active
- 2015-11-06 PL PL19174849T patent/PL3542812T3/pl unknown
- 2015-11-06 HU HUE19174849A patent/HUE053347T2/hu unknown
- 2015-11-06 CN CN201580060330.2A patent/CN107073072B/zh active Active
- 2015-11-06 SI SI201531539T patent/SI3542812T1/sl unknown
- 2015-11-06 JP JP2017523438A patent/JP6797795B2/ja active Active
- 2015-11-06 PL PL15791287T patent/PL3215173T3/pl unknown
- 2015-11-06 SI SI201531067T patent/SI3215173T1/sl unknown
- 2015-11-06 CA CA2964524A patent/CA2964524A1/en active Pending
- 2015-11-06 WO PCT/EP2015/075918 patent/WO2016071495A1/en active Application Filing
- 2015-11-06 BR BR112017009405-3A patent/BR112017009405B1/pt active IP Right Grant
- 2015-11-06 EP EP20215453.0A patent/EP3834837A1/en active Pending
- 2015-11-06 ES ES15791287T patent/ES2769849T3/es active Active
- 2015-11-06 PT PT157912874T patent/PT3215173T/pt unknown
-
2017
- 2017-04-18 PH PH12017500720A patent/PH12017500720A1/en unknown
- 2017-04-19 ZA ZA2017/02767A patent/ZA201702767B/en unknown
- 2017-05-01 SA SA517381446A patent/SA517381446B1/ar unknown
- 2017-05-04 IL IL252120A patent/IL252120B/en active IP Right Grant
- 2017-05-05 CL CL2017001139A patent/CL2017001139A1/es unknown
- 2017-05-26 CO CONC2017/0005391A patent/CO2017005391A2/es unknown
- 2017-11-30 US US15/827,719 patent/US10039804B2/en active Active
-
2018
- 2018-12-11 US US16/216,446 patent/US10849956B2/en active Active
-
2019
- 2019-11-07 US US16/677,057 patent/US11000567B2/en active Active
-
2020
- 2020-01-21 HR HRP20200101TT patent/HRP20200101T1/hr unknown
- 2020-03-20 CY CY20201100266T patent/CY1122960T1/el unknown
- 2020-07-20 JP JP2020123671A patent/JP7032488B2/ja active Active
-
2021
- 2021-03-01 HR HRP20210342TT patent/HRP20210342T8/hr unknown
- 2021-03-29 US US17/215,675 patent/US11628200B2/en active Active
- 2021-04-09 CY CY20211100307T patent/CY1124011T1/el unknown
-
2022
- 2022-07-08 US US17/860,642 patent/US11517609B2/en active Active
-
2023
- 2023-01-06 US US18/151,155 patent/US20230158101A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200101T1 (hr) | Glikopeptidni pripravci | |
| JP2017533218A5 (hr) | ||
| PH12017500844A1 (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| JP2019518733A5 (hr) | ||
| AR088460A1 (es) | Formulaciones de etanercept estabilizadas con aminoacidos | |
| CY1117710T1 (el) | Κρυσταλλικοι αναστολεις πρωτεασων εποξυ-κετονων πεπτιδιων και η συνθεση των κετο-εποξειδιων αμινοξεων | |
| RU2009137380A (ru) | Лиофилизированный препарат, содержащий гриппозную вакцину, и способ его получения | |
| BR112015023168A8 (pt) | composição de dicetopiperazina cristalina, métodos de produção de partículas de dicetopiiperazina,de produção de uma composição e de tratamento e uso de uma composição de dicetopiperazina cristalina | |
| NZ601374A (en) | Stabilized antibody-containing liquid formulations | |
| BR112015025958A2 (pt) | composição que contém corpos oleosos, ácidos graxos, tensoativos de aminoácido e n-metil-n-acilglucaminas | |
| IN2014DN03424A (hr) | ||
| BR112014000834A2 (pt) | compostos modificadores de sabor | |
| RU2014133818A (ru) | Стабилизированный состав pth | |
| MY165152A (en) | Cyclosporine analogue molecules modified at amino acid 1 and 3 | |
| EA201591276A1 (ru) | Фармацевтическая композиция с улучшенной биодоступностью | |
| PH12016501175A1 (en) | Formulations of deoxycholic acid and salts thereof | |
| BR112017008406A2 (pt) | uso de tripeptidil peptidases tolerantes a prolina em composições de aditivo alimentar | |
| IN2015DN03883A (hr) | ||
| WO2008046232A8 (en) | Aziridine aldehydes, aziridine-conjugated amino derivatives, aziridine-conjugated biomolecules and processes for their preparation | |
| MX2009011815A (es) | Particulas de liberacion modificadas basadas en polielectrolitos y en un principio activo y formulaciones farmaceuticas que contienen estas particulas. | |
| RU2018124983A (ru) | Пептидная композиция | |
| FR3066194B1 (fr) | Procede de synthese d'aminoacides n-acyles sans utiliser de solvants ni de chlorure d'acide | |
| WO2008096276A3 (en) | Peptide inhibitors of metallo- ectopeptidases, compositions comprising said compounds and their pharmaceutical and cosmetic uses | |
| CN104761398A (zh) | 一种荸荠氨基酸中草药复混肥 | |
| ATE504289T1 (de) | Ausstossflüssigkeit und ausstossverfahren |